Ionis Pharmaceuticals, Inc.
IONS
#1860
Rank
$10.529 B
Marketcap
United States
Country
$63.36
Share price
14.33%
Change (1 day)
-26.70%
Change (1 year)
Categories
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary…
Key Metrics
Trailing P/E
—
Forward P/E
-40.31
EPS (TTM)
$-3.30
Forward EPS
$-1.11
Price / Book
16.89
EV / EBITDA
-13.0x
Beta
0.42
Dividend Yield
—
Return on Equity
-105.50%
Return on Assets
-12.43%
Debt / Equity
497.80
Current Ratio
7.89
Gross Margin
-6.93%
Operating Margin
-38.18%
Net Profit Margin
-64.66%
Free Cash Flow
$-346,764,640
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 18 – Sep 16
-24.79%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$943.711M
Latest Net Income$-381,387,000
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Ionis Pharmaceuticals, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
IONS
No recent news available. Set FINNHUB_API_KEY to enable news.
